News

Lilly announces negative results in schizophrenia drug trial

BY Alaric DeArment

INDIANAPOLIS — A clinical trial of a drug for schizophrenia did not yield the desired results, the drug’s developer said.

Eli Lilly announced results of the H8Y-MC-HBBM study of pomaglumetad methionil, for patients with acute exacerbation of schizophrenia. The company said results did not show the drug produced a significantly different effect from the placebo.

"Unfortunately, negative studies are common in the field of psychiatry and a reality of biopharmaceutical innovation," Lilly Research Labs EVP science and technology and president Jan Lundberg said. "Despite all of the advances, the need for new and better treatments for those suffering with mental illnesses is among the most urgent in medicine."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Hy-Vee, Pinnaclife offer health demonstrations

BY Alaric DeArment

CORALVILLE, Iowa — A company that makes a line of dietary supplements is offering informal demonstrations on health at several Hy-Vee stores.

Pinnaclife said it would offer the demonstrations through July 21 at Hy-Vee stores in South Dakota, Minnesota, Iowa, Kansas and Missouri with Hy-Vee dietitians. The company, based in Coralville, Iowa, manufactures a mineral, vitamin and other supplements under the Olivamine brand.

"As a company dedicated to health and nutrition, we look at what Hy-Vee is doing with their Health Markets, NuVal system and dietitians," Pinnacle founder Darlene McCord said. "We believe that when a person shots at Hy-Vee, they have the best opportunity to make healthy choices. We are happy and excited to partner with them on this journey towards good health."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Meda Consumer introduces new look across its Feosol portfolio

BY Michael Johnsen

WHITE PLAINS, N.Y. — Brand strategy firm Little Big Brands on Thursday unveiled the new look for Meda Consumer Healthcare’s Feosol line of iron supplements.

Among the changes, each SKU has the pill form embossed and anchors the design at the bottom of the pack. A mix of spot and matte varnish provides depth, dimension and interest on shelf.

“You really have to applaud the Feosol brand team,” Little Big Brands creative dreictor John Nunziato said. “They were fearless in their approach to this redesign. … The new Feosol look is breakthrough in the category. It’s feminine without being cliché, and straightforward in a category that is notoriously hard to shop.”

The new packaging is rolling out nationwide this summer. 


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?